Abstract
Noncoding RNAs (ncRNAs), which make up a significant portion of the mammalian transcriptome and plays crucial regulatory roles in expression of genes and other biological processes, have recently been found. The most extensively researched of the sncRNAs, microRNAs (miRNAs), have been characterized in terms of their synthesis, roles, and significance in the tumor development. Its crucial function in the stem cell regulation, another class of sncRNAs known as aspirRNAs, has attracted attention in cancer research. The investigations have shown that long non-coding RNAs have a crucial role in controlling developmental stages, such as mammary gland development. Additionally, it has been discovered that lncRNA dysregulation precedes the development of several malignancies, including breast cancer. The functions of sncRNAs (including miRNAs and piRNAs) and lncRNAs in the onset and development of the breast cancer are described in this study. Additionally, future perspectives of various ncRNA-based diagnostic, prognostic, and therapeutic approaches also discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Data will be available on request.
Abbreviations
- BC:
-
Breast cancer
- snRNA:
-
Small non coding RNA
- lnRNA:
-
Long non-coding RNA
- tRNA:
-
Transfer RNA
- miRNAs:
-
Micro RNA
- tRFs:
-
Transfer RNA-derived RNA fragments
- CAF:
-
Cancer-associated fibroblast
- TNBC:
-
Triple negative breast cancer
- CircRNAs:
-
Circular RNAs
- HER2:
-
Human epidermal development factor receptor 2
References
Alexander RP, Fang G, Rozowsky J et al (2010) Annotating non-coding regions of the genome. Nat Rev Genet 11:559–571. https://doi.org/10.1038/nrg2814
Allegra CJ, Jessup JM, Somerfield MR et al (2009) American Society of Clinical Oncology Provisional Clinical Opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti–epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2096. https://doi.org/10.1200/JCO.2009.21.9170
Arriaga-Canon C, Contreras-Espinosa L, Aguilar-Villanueva S et al (2023) The clinical utility of lncRNAs and their application as molecular biomarkers in breast cancer. Int J Mol Sci 24:7426. https://doi.org/10.3390/ijms24087426
Bachmayr-Heyda A, Reiner AT, Auer K et al (2015) Correlation of circular RNA abundance with proliferation — exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis and normal human tissues. Sci Rep 5:8057. https://doi.org/10.1038/srep08057
Baroni S, Romero-Cordoba S, Plantamura I et al (2016) Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. Cell Death Dis 7:e2312–e2312. https://doi.org/10.1038/cddis.2016.224
Beg A, Khan FI, Lobb KA et al (2019) High throughput screening, docking, and molecular dynamics studies to identify potential inhibitors of human calcium/calmodulin-dependent protein kinase IV. J Biomol Struct Dyn 37:2179–2192. https://doi.org/10.1080/07391102.2018.1479310
Beg A, Parveen R (2022) Gene expression signature: an influential access to drug discovery in ovarian cancer. In: Raza K (ed) Computational intelligence in oncology. Springer Singapore, Singapore, pp 271–284
Beg A, Parveen R (2022b) Review of bioinformatics tools and techniques to accelerate ovarian cancer research. Int J Bioinforma Intell Comput 1:01–10
Beg A, Parveen R, Fouad H et al (2022) Role of different non-coding RNAs as ovarian cancer biomarkers. J Ovarian Res 15:72. https://doi.org/10.1186/s13048-022-01002-3
Beg A, Parveen R, Fouad H et al (2023) Identification of driver genes and miRNAs in ovarian cancer through an integrated in-silico approach. Biology 12:192. https://doi.org/10.3390/biology12020192
Bertone P, Stolc V, Royce TE et al (2004) Global identification of human transcribed sequences with genome tiling arrays. Science 306:2242–2246. https://doi.org/10.1126/science.1103388
Bombonati A, Sgroi DC (2011) The molecular pathology of breast cancer progression. J Pathol 223:308–318. https://doi.org/10.1002/path.2808
Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Buerger H, Otterbach F, Simon R et al (1999) Comparative genomic hybridization of ductal carcinomain situ of the breast? Evidence of multiple genetic pathways. J Pathol 187:396–402. https://doi.org/10.1002/(SICI)1096-9896(199903)187:4%3c396::AID-PATH286%3e3.0.CO;2-L
Byler S, Goldgar S, Heerboth S et al (2014) Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res 34:1071–1077
Camps C, Saini HK, Mole DR et al (2014) Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia. Mol Cancer 13:28. https://doi.org/10.1186/1476-4598-13-28
Carninci P, Kasukawa T, Katayama S et al (2005) The transcriptional landscape of the mammalian genome. Science 309:1559–1563. https://doi.org/10.1126/science.1112014
Chandra Gupta S, Nandan Tripathi Y (2017) Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets: Long non-coding RNAs in cancer patients. Int J Cancer 140:1955–1967. https://doi.org/10.1002/ijc.30546
Chen S, Liu B, Xu J et al (2015) MiR-449a suppresses the epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by multiple targets. BMC Cancer 15:706. https://doi.org/10.1186/s12885-015-1738-3
Chen T, Wang X, Li C et al (2021) CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation. Oncogene 40:2756–2771. https://doi.org/10.1038/s41388-021-01739-z
Chen Y-W, Chou H-C, Lyu P-C et al (2011) Mitochondrial proteomics analysis of tumorigenic and metastatic breast cancer markers. Funct Integr Genomics 11:225–239. https://doi.org/10.1007/s10142-011-0210-y
Cheng J, Deng H, Xiao B et al (2012) piR-823, a novel non-coding small RNA, demonstrates in vitro and in vivo tumor suppressive activity in human gastric cancer cells. Cancer Lett 315:12–17. https://doi.org/10.1016/j.canlet.2011.10.004
Chi Y, Huang S, Yuan L et al (2014) Role of BC040587 as a predictor of poor outcome in breast cancer. Cancer Cell Int 14:123. https://doi.org/10.1186/s12935-014-0123-7
Chu M, Fang Y,Jin Y (2021) CircRNAs as promising biomarker in diagnosis of breast cancer: an updated meta‐analysis. J Clin Lab Anal 35. https://doi.org/10.1002/jcla.23934
Ciravolo V, Huber V, Ghedini GC et al (2012) Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol 227:658–667. https://doi.org/10.1002/jcp.22773
Cuykendall TN, Rubin MA, Khurana E (2017) Non-coding genetic variation in cancer. Curr Opin Syst Biol 1:9–15. https://doi.org/10.1016/j.coisb.2016.12.017
Di Agostino S, Vahabi M, Turco C, Fontemaggi G (2022) Secreted non-coding RNAs: functional impact on the tumor microenvironment and clinical relevance in triple-negative breast cancer. Non-Coding RNA 8:5. https://doi.org/10.3390/ncrna8010005
Ding X, Zhu L, Ji T et al (2014) Long intergenic non-coding RNAs (LincRNAs) identified by RNA-Seq in breast cancer. PLoS ONE 9:e103270. https://doi.org/10.1371/journal.pone.0103270
Djebali S, Davis CA, Merkel A et al (2012) Landscape of transcription in human cells. Nature 489:101–108. https://doi.org/10.1038/nature11233
Eichner LJ, Perry M-C, Dufour CR et al (2010) miR-378 ∗ mediates metabolic shift in breast cancer cells via the PGC-1β/ERRγ transcriptional pathway. Cell Metab 12:352–361. https://doi.org/10.1016/j.cmet.2010.09.002
Esseghir S, Reis-Filho J, Kennedy A et al (2006) Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts. J Pathol 210:420–430. https://doi.org/10.1002/path.2071
Esseghir S, Todd SK, Hunt T et al (2007) A role for glial cell–derived neurotrophic factor–induced expression by inflammatory cytokines and RET/GFRα1 receptor up-regulation in breast cancer. Cancer Res 67:11732–11741. https://doi.org/10.1158/0008-5472.CAN-07-2343
Evans JR, Feng FY, Chinnaiyan AM (2016) The bright side of dark matter: lncRNAs in cancer. J Clin Invest 126:2775–2782. https://doi.org/10.1172/JCI84421
Fan C-N, Ma L, Liu N (2018) Systematic analysis of lncRNA–miRNA–mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer. J Transl Med 16:264. https://doi.org/10.1186/s12967-018-1640-2
Fong MY, Zhou W, Liu L et al (2015) Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol 17:183–194. https://doi.org/10.1038/ncb3094
Hansen TB, Jensen TI, Clausen BH et al (2013) Natural RNA circles function as efficient microRNA sponges. Nature 495:384–388. https://doi.org/10.1038/nature11993
Hirschfeld M, Rücker G, Weiß D et al (2020) Urinary exosomal microRNAs as potential non-invasive biomarkers in breast cancer detection. Mol Diagn Ther 24:215–232. https://doi.org/10.1007/s40291-020-00453-y
Huang N, Chi Y, Xue J et al (2016) Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer. Oncotarget 7:37957–37965. https://doi.org/10.18632/oncotarget.9364
Huang Q-Y, Liu G-F, Qian X-L et al (2019) Long non-coding RNA: dual effects on breast cancer metastasis and clinical applications. Cancers 11:1802. https://doi.org/10.3390/cancers11111802
Huang Y (2018) The novel regulatory role of lncRNA-miRNA-mRNA axis in cardiovascular diseases. J Cell Mol Med 22:5768–5775. https://doi.org/10.1111/jcmm.13866
Huang Z, Qin Q, Xia L et al (2021) Significance of Oncotype DX 21-gene test and expression of long non-coding RNA MALAT1 in early and estrogen receptor-positive breast cancer patients. Cancer Manag Res 13:587–593. https://doi.org/10.2147/CMAR.S276795
Iorio MV, Ferracin M, Liu C-G et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065–7070. https://doi.org/10.1158/0008-5472.CAN-05-1783
Ishizu H, Siomi H, Siomi MC (2012) Biology of PIWI-interacting RNAs: new insights into biogenesis and function inside and outside of germlines. Genes Dev 26:2361–2373. https://doi.org/10.1101/gad.203786.112
Kim VN (2006) Small RNAs just got bigger: Piwi-interacting RNAs (piRNAs) in mammalian testes. Genes Dev 20:1993–1997. https://doi.org/10.1101/gad.1456106
Kong W, He L, Richards EJ et al (2014) Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 33:679–689. https://doi.org/10.1038/onc.2012.636
Kovalchuk O, Filkowski J, Meservy J et al (2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7:2152–2159. https://doi.org/10.1158/1535-7163.MCT-08-0021
Lehmann BD, Colaprico A, Silva TC et al (2021) Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun 12:6276. https://doi.org/10.1038/s41467-021-26502-6
Leucci E (2018) Cancer development and therapy resistance: spotlights on the dark side of the genome. Pharmacol Ther 189:22–30. https://doi.org/10.1016/j.pharmthera.2018.04.001
Li L, Xiao B, Tong H et al (2012) Regulation of breast cancer tumorigenesis and metastasis by miRNAs. Expert Rev Proteomics 9:615–625. https://doi.org/10.1586/epr.12.64
Li M, Zhou Y, Xia T et al (2018) Circulating microRNAs from the miR-106a–363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer. Breast Cancer Res Treat 170:257–270. https://doi.org/10.1007/s10549-018-4757-3
Li T, Chen S, Zhang Y et al (2023) Ensemble learning-based gene signature and risk model for predicting prognosis of triple-negative breast cancer. Funct Integr Genomics 23:81. https://doi.org/10.1007/s10142-023-01009-z
Li Y, Pei J, Xia H et al (2003) Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene 22:4398–4405. https://doi.org/10.1038/sj.onc.1206603
Lian Y, Xiong F, Yang L et al (2018) Long noncoding RNA AFAP1-AS1 acts as a competing endogenous RNA of miR-423-5p to facilitate nasopharyngeal carcinoma metastasis through regulating the Rho/Rac pathway. J Exp Clin Cancer Res 37:253. https://doi.org/10.1186/s13046-018-0918-9
Liang G, Liu Z, Tan L et al (2017) HIF1α-associated circDENND4C promotes proliferation of breast cancer cells in hypoxic environment. Anticancer Res 37:4337–4343. https://doi.org/10.21873/anticanres.11827
Liberti MV, Locasale JW (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41:211–218. https://doi.org/10.1016/j.tibs.2015.12.001
Lin J, Handschin C, Spiegelman BM (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1:361–370. https://doi.org/10.1016/j.cmet.2005.05.004
Liu Q, Wang Z, Kong X et al (2020) A novel prognostic signature of mRNA-lncRNA in breast cancer. DNA Cell Biol 39:671–682. https://doi.org/10.1089/dna.2019.5223
Liu X, Cao M, Palomares M et al (2018) Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res 20:127. https://doi.org/10.1186/s13058-018-1059-y
Lo P-K, Wolfson B, Zhou X et al (2016) Noncoding RNAs in breast cancer. Brief Funct Genomics 15:200–221. https://doi.org/10.1093/bfgp/elv055
Loganathan T, Doss CGP (2023) Non-coding RNAs in human health and disease: potential function as biomarkers and therapeutic targets. Funct Integr Genomics 23:33. https://doi.org/10.1007/s10142-022-00947-4
Lopez-Garcia MA, Geyer FC, Lacroix-Triki M et al (2010) Breast cancer precursors revisited: molecular features and progression pathways: Molecular evolution of breast cancer. Histopathology 57:171–192. https://doi.org/10.1111/j.1365-2559.2010.03568.x
Lü L, Sun J, Shi P et al (2017) Identification of circular RNAs as a promising new class of diagnostic biomarkers for human breast cancer. Oncotarget 8:44096–44107. https://doi.org/10.18632/oncotarget.17307
Luengo-Gil G, Gonzalez-Billalabeitia E, Perez-Henarejos SA et al (2018) Angiogenic role of miR-20a in breast cancer. Plos One 13:e0194638. https://doi.org/10.1371/journal.pone.0194638
Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449:682–688. https://doi.org/10.1038/nature06174
Ma L, Young J, Prabhala H et al (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12:247–256. https://doi.org/10.1038/ncb2024
Madhavan D, Zucknick M, Wallwiener M et al (2012) Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res 18:5972–5982. https://doi.org/10.1158/1078-0432.CCR-12-1407
Manjang K, Tripathi S, Yli-Harja O et al (2021) Prognostic gene expression signatures of breast cancer are lacking a sensible biological meaning. Sci Rep 11:156. https://doi.org/10.1038/s41598-020-79375-y
McFate T, Mohyeldin A, Lu H et al (2008) Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 283:22700–22708. https://doi.org/10.1074/jbc.M801765200
Milevskiy MJG, Al-Ejeh F, Saunus JM et al (2016) Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer. Hum Mol Genet 25:3269–3283. https://doi.org/10.1093/hmg/ddw177
Najafi S (2022) Circular RNAs as emerging players in cervical cancer tumorigenesis; a review to roles and biomarker potentials. Int J Biol Macromol 206:939–953. https://doi.org/10.1016/j.ijbiomac.2022.03.103
Najafi S (2023) The emerging roles and potential applications of circular RNAs in ovarian cancer: a comprehensive review. J Cancer Res Clin Oncol 149:2211–2234. https://doi.org/10.1007/s00432-022-04328-z
Najafi S, Khatami SH, Khorsand M et al (2022) Long non-coding RNAs (lncRNAs); roles in tumorigenesis and potentials as biomarkers in cancer diagnosis. Exp Cell Res 418:113294. https://doi.org/10.1016/j.yexcr.2022.113294
Nguyen Q-H, Nguyen H, Nguyen T, Le D-H (2020) Multi-omics analysis detects novel prognostic subgroups of breast cancer. Front Genet 11:574661. https://doi.org/10.3389/fgene.2020.574661
Ou F-S, Michiels S, Shyr Y et al (2021) Biomarker discovery and validation: statistical considerations. J Thorac Oncol 16:537–545. https://doi.org/10.1016/j.jtho.2021.01.1616
Pan Y, Zhang Q, Zhang H, Kong F (2023) Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer. Funct Integr Genomics 23:38. https://doi.org/10.1007/s10142-023-00963-y
Pandey AK, Zhang Y, Zhang S et al (2015) TIP60-miR-22 axis as a prognostic marker of breast cancer progression. Oncotarget 6:41290–41306. https://doi.org/10.18632/oncotarget.5636
Peinado H, Alečković M, Lavotshkin S et al (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18:883–891. https://doi.org/10.1038/nm.2753
Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752. https://doi.org/10.1038/35021093
Raposo G, Stoorvogel W (2013) Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 200:373–383. https://doi.org/10.1083/jcb.201211138
Rasool M, Malik A, Zahid S et al (2016) Non-coding RNAs in cancer diagnosis and therapy. Non-Coding RNA Res 1:69–76. https://doi.org/10.1016/j.ncrna.2016.11.001
Ratkaj I, Stajduhar E, Vucinic S et al (2010) Integrated gene networks in breast cancer development. Funct Integr Genomics 10:11–19. https://doi.org/10.1007/s10142-010-0159-2
Ren S, Wang F, Shen J et al (2013) Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer 49:2949–2959. https://doi.org/10.1016/j.ejca.2013.04.026
Sahai E, Astsaturov I, Cukierman E et al (2020) A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer 20:174–186. https://doi.org/10.1038/s41568-019-0238-1
Sempere LF, Christensen M, Silahtaroglu A et al (2007) Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67:11612–11620. https://doi.org/10.1158/0008-5472.CAN-07-5019
Sha L-Y, Zhang Y, Wang W et al (2016) MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer. Eur Rev Med Pharmacol Sci 20:2201–2208
Sharp JA, Lefèvre C, Watt A, Nicholas KR (2016) Analysis of human breast milk cells: gene expression profiles during pregnancy, lactation, involution, and mastitic infection. Funct Integr Genomics 16:297–321. https://doi.org/10.1007/s10142-016-0485-0
Shi Y, Li J, Liu Y et al (2015) The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression. Mol Cancer 14:51. https://doi.org/10.1186/s12943-015-0318-0
Shin VY, Siu JM, Cheuk I et al (2015) Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer 112:1751–1759. https://doi.org/10.1038/bjc.2015.143
Shirvani H, Ghanavi J, Aliabadi A et al (2023) MiR-211 plays a dual role in cancer development: From tumor suppressor to tumor enhancer. Cell Signal 101:110504. https://doi.org/10.1016/j.cellsig.2022.110504
Siddiqi S, Matushansky I (2012) Piwis and piwi-interacting RNAs in the epigenetics of cancer. J Cell Biochem 113:373–380. https://doi.org/10.1002/jcb.23363
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015: Cancer Statistics, 2015. CA Cancer J Clin 65:5–29. https://doi.org/10.3322/caac.21254
Singh R, Pochampally R, Watabe K et al (2014) Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Mol Cancer 13:256. https://doi.org/10.1186/1476-4598-13-256
Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98:10869–10874. https://doi.org/10.1073/pnas.191367098
Sørlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci 100:8418–8423. https://doi.org/10.1073/pnas.0932692100
Spizzo R, Almeida MI, Colombatti A, Calin GA (2012) Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene 31:4577–4587. https://doi.org/10.1038/onc.2011.621
Sriroopreddy R, Sudandiradoss C (2018) Integrative network-based approach identifies central genetic and transcriptomic elements in triple-negative breast cancer. Funct Integr Genomics 18:113–124. https://doi.org/10.1007/s10142-017-0579-3
Tanimoto K (2000) Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19:4298–4309. https://doi.org/10.1093/emboj/19.16.4298
Teo AYT, Xiang X, Le MT et al (2021) Tiny miRNAs play a big role in the treatment of breast cancer metastasis. Cancers (Basel) 2021;13(2):337. https://doi.org/10.3390/cancers13020337
Teplyuk NM, Mollenhauer B, Gabriely G et al (2012) MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro-Oncol 14:689–700. https://doi.org/10.1093/neuonc/nos074
The ENCODE Project Consortium (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447:799–816. https://doi.org/10.1038/nature05874
Valadi H, Ekström K, Bossios A et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654–659. https://doi.org/10.1038/ncb1596
van Doormaal FF, Kleinjan A, Di Nisio M et al (2009) Cell-derived microvesicles and cancer. Neth J Med 67:266–273
Wang X, Fang L (2018) Advances in circular RNAs and their roles in breast Cancer. J Exp Clin Cancer Res 37:206. https://doi.org/10.1186/s13046-018-0870-8
Wang Z, Mehmood A, Yao J et al (2023) Combination of furosemide, gold, and dopamine as a potential therapy for breast cancer. Funct Integr Genomics 23:94. https://doi.org/10.1007/s10142-023-01007-1
Wu Z-S, Pandey V, Wu W-Y et al (2013) Prognostic significance of the expression of GFRα1, GFRα3 and Syndecan-3, proteins binding ARTEMIN, in mammary carcinoma. BMC Cancer 13:34. https://doi.org/10.1186/1471-2407-13-34
Xia M, Feng S, Chen Z et al (2020) Non-coding RNAs: key regulators of aerobic glycolysis in breast cancer. Life Sci 250:117579. https://doi.org/10.1016/j.lfs.2020.117579
Xin L, Liu Y-H, Martin TA, Jiang WG (2017) The era of multigene panels comes? The clinical utility of oncotype DX and MammaPrint. World J Oncol 8:34–40. https://doi.org/10.14740/wjon1019w
Yan W, Wu X, Zhou W et al (2018) Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol 20:597–609. https://doi.org/10.1038/s41556-018-0083-6
Ye Q, Wang X, Yuan M et al (2021) miR-219-5p targets TBXT and inhibits breast cancer cell EMT and cell migration and invasion. Biosci Rep 41:BSR20210318. https://doi.org/10.1042/BSR20210318
Yu F, Yao H, Zhu P et al (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131:1109–1123. https://doi.org/10.1016/j.cell.2007.10.054
Zhang L, Liu C, Zhang X et al (2023) Breast cancer prognosis and immunological characteristics are predicted using the m6A/m5C/m1A/m7G-related long noncoding RNA signature. Funct Integr Genomics 23:117. https://doi.org/10.1007/s10142-023-01026-y
Zhang L, Song X, Wang X et al (2015) Circulating DNA of HOTAIR in serum is a novel biomarker for breast cancer. Breast Cancer Res Treat 152:199–208. https://doi.org/10.1007/s10549-015-3431-2
Zhao W, Luo J, Jiao S (2014) Comprehensive characterization of cancer subtype associated long non-coding RNAs and their clinical implications. Sci Rep 4:6591. https://doi.org/10.1038/srep06591
Zhao Y, Li H, Fang S et al (2016) NONCODE 2016: an informative and valuable data source of long non-coding RNAs. Nucleic Acids Res 44:D203–D208. https://doi.org/10.1093/nar/gkv1252
Zhong L, Lou G, Zhou X et al (2017) A six-long non-coding RNAs signature as a potential prognostic marker for survival prediction of ER-positive breast cancer patients. Oncotarget 8:67861–67870. https://doi.org/10.18632/oncotarget.18919
Zhu N, Zhang D, Xie H et al (2011) Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol Cell Biochem 351:157–164. https://doi.org/10.1007/s11010-011-0723-7
Acknowledgements
Shadma Wahab extend their appreciation to the Deanship of Scientific Research at King Khalid University for supporting through Large Groups Project under grant number (RGP.2/119/44).
Funding
Shadma Wahab received funding from the Deanship of Scientific Research at King Khalid University for this work through the Large Research Groups Project under grant number (RGP.2/119/44).
Author information
Authors and Affiliations
Contributions
RA and NJ Khan conceptualized the work. RA and SAL write the manuscript. SAL prepared the figures. NJ Khan refined the manuscript. All authors contributed to the article and approved the submitted version. Shadma Wahab and Mohammad Khalid assisted in manuscript revision.
Corresponding author
Ethics declarations
Institutional review board statement
Not applicable.
Informed consent
Not applicable.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ali, R., Laskar, S.A., Khan, N.J. et al. Non-coding RNA’s prevalence as biomarkers for prognostic, diagnostic, and clinical utility in breast cancer. Funct Integr Genomics 23, 195 (2023). https://doi.org/10.1007/s10142-023-01123-y
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10142-023-01123-y